These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 20564351)

  • 21. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.
    Lee YB; Nam JY; Lee JH; Chang Y; Cho H; Cho YY; Cho EJ; Yu SJ; Kim HY; Lee DH; Lee JM; Hwang SG; Kim YJ; Yoon JH
    Sci Rep; 2018 Sep; 8(1):13651. PubMed ID: 30209336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
    Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
    Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
    Yoshida EM; Sherman M; Bain VG; Cooper CL; Deschênes M; Marotta PJ; Lee SS; Krajden M; Witt-Sullivan H; Bailey RJ; Usaty C; Peltekian K;
    Can J Gastroenterol; 2009 Mar; 23(3):180-4. PubMed ID: 19319382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
    Pinzone MR; Zanghì AM; Rapisarda L; D'Agata V; Benanti F; Spartà D; Nunnari G; Cacopardo B
    Eur Rev Med Pharmacol Sci; 2014 Dec; 18(2 Suppl):11-5. PubMed ID: 25535185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
    Chen TM; Lin CC; Huang PT; Wen CF
    Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
    Lee HW; Chon YE; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Jung KS; Park YN; Han KH
    Gut Liver; 2016 May; 10(3):429-36. PubMed ID: 26347515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
    Harada N; Hiramatsu N; Oze T; Yamada R; Kurokawa M; Miyazaki M; Yakushijin T; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Gastroenterol; 2013 Apr; 48(4):535-43. PubMed ID: 22976932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of interferon-based therapy for chronic hepatitis C.
    Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
    Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
    Ueda Y; Marusawa H; Kaido T; Ogura Y; Oike F; Mori A; Ogawa K; Yoshizawa A; Hatano E; Miyagawa-Hayashino A; Haga H; Egawa H; Takada Y; Uemoto S; Chiba T
    J Viral Hepat; 2012 Jan; 19(1):32-8. PubMed ID: 21129128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
    Wang X; Gao F; Yuan G; Shi K; Huang Y; Chen Y; Qiu R; Sun L; Liu J; Hu C; Zhou Y
    J Viral Hepat; 2016 Dec; 23(12):971-976. PubMed ID: 27453300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.